TN-CKE-RESTAURANTS
CKE Restaurants Holdings, Inc., the parent company of Carl’s Jr. and Hardee’s , announced the opening of its 1,000th international restaurant in Madrid, Spain, as they continue to bring bold, craveable burgers and flavors to all corners of the globe. The opening marks a key milestone for the brand as it continues to expand its international footprint across Europe, the Americas, Asia, the Middle East, Australia and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005062/en/
The opening of the new Carl’s Jr. restaurant in Madrid marks the 23rd restaurant in Spain. CKE is continuing to expand across the European market, all the while, delivering new, innovative customer experiences and a menu filled with its impossible-to-ignore flavors.
“The opening of the 1000th international location is a proud moment placing CKE in the top tier of global restaurant chains,” said CEO of CKE Restaurants Ned Lyerly. “Our momentum is building as we have plans to double our international presence in the next five years. We will accelerate growth by focusing on partnerships with exceptional franchise operators who share our vision of offering the most innovative, best tasting food in our industry!”
CKE continues to expand its presence across six continents and has maintained positive same store sales globally for nearly a decade. Earlier this year, the company hit other pivotal international milestones, including opening its 300th restaurant in Mexico; celebrating 40 years of business in the Middle East; expanding across Australia with a flagship restaurant opening in Sydney and later this summer the company will open a restaurant in Charles de Gaulle Airport centered around speed and convenience with a “Grab & Go” station, self-order kiosks and more.
“The 1,000th international restaurant is a major milestone for our company, and we’re thrilled to be able to continue providing guests around the world an iconic taste of California,” said Mike Woida, President of CKE International . “This new Carl’s Jr. location in Spain exemplifies CKE’s commitment to adapt to the consumer landscape and offer new experiences while maintaining craveable flavors.”
With culinary innovation at the forefront, CKE Restaurants will continue to introduce mouth-watering flavors that highlight their brands’ Chargrilled Angus Beef Burgers, crispy Hand-Breaded Chicken Tenders™, their iconic range of products that everyone knows and loves, and additionally CKE will create local adaptations that are region-specific, such as the Morita Burger in Mexico, Poutine in Canada, and more.
Follow Carl’s Jr. and Hardee’s on social media for the latest product news and promotional offers.
Twitter:
@CarlsJr
and @Hardees
Instagram:
@CarlsJr
and @Hardees
Facebook:
www.facebook.com/carlsjr
and www.facebook.com/hardees
About CKE Restaurants Holdings, Inc.
CKE Restaurants Holdings, Inc. (“CKE”), a privately held company based in Franklin, Tennessee, runs and operates Carl’s Jr. and Hardee’s, two beloved regional brands, known for one-of-a-kind premium and innovative menu items such as 100 percent Black Angus Thickburgers®, Made from Scratch™ Biscuits and Hand-Breaded Chicken Tenders™. With both a US and international footprint, Carl’s Jr. Restaurants LLC and Hardee’s Restaurants LLC have over 3,900 franchised or company-operated restaurants in 44 states and 40 foreign countries and U.S. territories. For more information about CKE, please visit www.ckr.com or its brand sites at www.carlsjr.com and www.hardees.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom